Previous 10 | Next 10 |
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Offi...
2024-02-26 08:50:00 ET The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem likely to happen in the next de...
2024-02-21 16:20:58 ET Summary Auvelity shows growth with $130.1 million annual sales, impressive in a crowded depression treatment market. Axsome's Q4 reveals surging revenues but widened losses due to high R&D and SG&A expenses. The cash position is strong, however, ...
2024-02-20 18:47:07 ET Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Conference Call February 20, 2024 08:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer ...
2024-02-20 18:00:16 ET Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q4 2023 Earnings Call Feb 20, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Tran...
2024-02-20 07:10:40 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story Axsome Therapeutics Q4 2023 Earnings Preview UBS starts Axsome at buy, sees Au...
Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million, respectively, during the first full year of launch...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...
2024-02-16 13:24:18 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story UBS starts Axsome at buy, sees Auvelity hitting $1B sales by 2030 Axsome Thera...
2024-02-08 18:05:29 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story Axsome Therapeutics a new outperform at RBC on underappreciated pipeline New A...
News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Inc. Company Name:
AXSM Stock Symbol:
NASDAQ Market:
Axsome Therapeutics Inc. Website:
2024-05-18 06:47:00 ET If you go to California's Redwood National Park, you can see the world's tallest tree -- a redwood called Hyperion that's over 380 feet tall. Like every other tree, though, Hyperion started as a small seed. Stocks can be like this, beginning small but growing to a...
2024-05-11 09:00:00 ET Stocks that can triple in six years aren't easy to find. Doing so requires a compound annual growth rate of 20.1%, well above the broader market's historical performance. However, it isn't impossible. Let's consider two stocks that may have what it takes to pull i...